Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.
Summary of "Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features."
Aim:  The aim of this study was to investigate the expression levels of hepatocyte growth factor (HGF) and thrombospondin-1 (TSP-1) with the clinical pathological factors in ovarian cancer, and the correlation between HGF and TSP-1 expression at the protein level. Material and Methods:  Immunohistochemistry was applied to detect the location and expression of HGF and TSP-1 protein in ovarian cancer and benign ovarian tumor tissue. Real-time quantitative polymerase chain reaction was applied to detect HGF and TSP-1 gene mRNA expression in ovarian cancer and benign ovarian tumor tissue. Results:  The level and positive expression rate of HGF mRNA in ovarian cancer tissue was significantly higher than in ovarian adenoma tissues. The positive expression of HGF protein in ovarian cancer was related with International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis. The level and positive expression rate of TSP-1 mRNA in ovarian cancer tissue was lower than in ovarian adenoma. The absence expression of TSP-1 protein in ovarian cancer was significantly related with FIGO stage and histological grade. The intensity of these positive expressions in ovarian cancer tissues were significant negatively associated with each other. Conclusion:  Abnormal expression of HGF and TSP-1 may be related to malignant progression of ovarian cancer and associated in the pathogenesis of ovarian cancer.
Affiliation
Departments of Obstetrics and Gynecology Basic Medicine, Qilu Hospital of Shandong University Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Shandong, China.
Journal Details
This article was published in the following journal.
Name: The journal of obstetrics and gynaecology research
ISSN: 1341-8076
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22136730
- DOI: http://dx.doi.org/10.1111/j.1447-0756.2011.01695.x
Medical and Biotech [MESH] Definitions
Carcinoma, Endometrioid
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
Primary Ovarian Insufficiency
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
Ovarian Failure, Premature
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
Carcinoma, Bronchogenic
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Gerstmann-straussler-scheinker Disease
An autosomal dominant familial prion disease with a wide spectrum of clinical presentations including ATAXIA, spastic paraparesis, extrapyramidal signs, and DEMENTIA. Clinical onset is in the third to sixth decade of life and the mean duration of illness prior to death is five years. Several kindreds with variable clinical and pathologic features have been described. Pathologic features include cerebral prion protein amyloidosis, and spongiform or neurofibrillary degeneration. (From Brain Pathol 1998 Jul;8(3):499-513; Brain Pathol 1995 Jan;5(1):61-75)
PubMed Articles
It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene in several types of human cancer. The potential oncogenic role of EZH2 and its clinical/prognostic si...
Aim:  Endometrioid carcinoma of the ovary is the third most common type of epithelial ovarian cancer. Endometrioid tumors as well as endometriotic implants are characterized by the presence of epith...
Recent evidence suggests that the chemokine axis of CXC chemokine ligand-12 and its receptor CXC chemokine receptor-4 (CXCL12/CXCR4) is highly expressed in gynecological tumors and the axis of CXC che...
LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis.
LAPTM4B is a novel tumor-associated gene. To date, there have been no published data regarding the role of LAPTM4B expression in epithelial ovarian carcinoma metastasis. Therefore, the present study w...
The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
BACKGROUND: Folate receptor alpha (FR-α) has been identified as a potential target in ovarian cancer for diagnostic and therapeutic purposes, based on its overexpression in serous epithelial ovarian...
Clinical Trials
The purpose of this study is to assess the effectiveness and safety of pegylated liposomal doxorubicin hydrochloride injection in Japanese patients with Mullerian carcinoma. This clinical...
PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion
We have identified insulin-like growth factor binding protein (IGFBP)-3 as an invasion suppressor gene in ovarian endometrioid carcinoma, and showed association with lower cancer migration...
Mesothelin as a New Tumor Marker for Ovarian Cancer
Ovarian cancer became a more and more important disease in recent years due to its first mortality rate of gynecologic malignancies. The incidence of ovarian cancer also increased in recen...
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administe...
